Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Polycystic Ovary Syndrome 1Ovarian Hyperstimulation Syndrome 1

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 10human papillomavirus vaccine, L1 type 16, 18 7olaparib 4niraparib 4Human Papillomavirus Recombinant Vaccine nonavalent 4Vaccines 3Saline Solution 3Papillomavirus Vaccines 3Medroxyprogesterone Acetate 3Carboplatin 3Bevacizumab 3pegylated granulocyte colony-stimulating factor 2liposomal doxorubicin 2fluciclovine F-18 2apatinib 2Sevoflurane 2Propofol 2Paclitaxel 2Aspirin 2semaglutide 1pegfilgrastim 1pazopanib 1palbociclib 1lenvatinib 1halofantrine 1ganirelix 1gadofosveset trisodium 1fosaprepitant 1follicle stimulating hormone, human, with HCG C-terminal peptide 1ferrous gluconate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Profasi × Gynecologic × Clear all
NCT01815138 2018-10-26

Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS

UConn Health

Phase 4 Completed
89 enrolled 13 charts
Gynecologic

Polycystic Ovary Syndrome, Ovarian Hyperstimulation Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡